Stator (Rosuvastatin)

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Stator (Rosuvastatin)

Quick Facts

Property Description
Active ingredient Rosuvastatin calcium
Form Oral film-coated tablet
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
Common use Lipid-modifying agent (cholesterol reduction)
Origin Synthetic compound
Rx Status Prescription-only

What Type of Medicine is Stator (Rosuvastatin) and What is its Purpose?

Stator is a prescription-only medication with the active ingredient Rosuvastatin calcium, formally classified as an HMG-CoA Reductase Inhibitor. This category is widely known as the statin class of drugs. Rosuvastatin is distinguished within this class by its high potency and unique chemical structure, making it one of the agents used for regulating circulating fats. The general purpose of Stator is to act as a lipid-modifying agent used for patients needing management of elevated lipid levels.

Its action in reducing low-density lipoprotein cholesterol (LDL-C) is based on its pharmacological properties. This medicine works within the body to help maintain a healthier balance of blood lipids, and its principal function is addressing high levels of circulating cholesterol.

Composition and Physical Form of Rosuvastatin

The core of the product is the active substance, Rosuvastatin calcium, which is a highly standardized, synthetic molecule. This compound is manufactured as an oral, film-coated tablet, a presentation designed for stability and accurate dose delivery via the oral route. Rosuvastatin is considered a single-component product whose action is initiated after systemic absorption. A key differentiating factor is its hydrophilic nature, which contributes to a predictable pharmacokinetic profile compared to some other statins. The underlying mechanism involves inhibiting the enzyme that controls the initial, rate-limiting step of cholesterol biosynthesis, thereby suppressing the body's internal production of cholesterol.

Regulatory References

  1. Rosuvastatin Drug Information - MedlinePlus
Advertisements

What side effects are possible with Stator (Rosuvastatin)?

Possible Side Effects and Safety Information

The safety profile for Stator (Rosuvastatin) is established by regulatory authorities through classifications based on frequency and affected body systems. These classifications define the scope of potential adverse reactions, ensuring a clear, neutral description of the medicine's risk profile.

Frequency-Classified Adverse Reactions

Adverse reactions are organized into official frequency categories derived from clinical data:

  • Common (e.g., muscle pain or myalgia, headache, dizziness, nausea, constipation, abdominal pain, asthenia).
  • Uncommon (e.g., pruritus, rash, urticaria).
  • Rare (e.g., myopathy, rhabdomyolysis, pancreatitis, increased hepatic transaminases).
  • Very Rare (e.g., hepatitis, jaundice, haematuria).

Serious Adverse Reactions and Systemic Effects

Regulatory documents highlight serious adverse reactions that affect major physiological systems. These include potentially severe events such as Rhabdomyolysis, which involves skeletal muscle breakdown, and Hepatitis or Jaundice, which concern liver function. Reactions are often grouped by System-Organ Class, affecting the Musculoskeletal system, Hepatobiliary system, and Nervous System.

Safety Restrictions and Special Populations

Official labels define specific safety constraints. Rosuvastatin is formally contraindicated in patients with active liver disease and those with severe renal impairment. Furthermore, population-specific safety notes address groups such as older adults (who may require increased monitoring for muscle-related effects) and Asian patients (due to documented higher systemic exposure). Time-related safety patterns note that the occurrence of proteinuria is more frequently observed during dose escalation.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Urgent Help

Overexposure to Rosuvastatin is not associated with a distinct set of acute symptoms; the regulatory profile focuses on the risk of exacerbating known severe toxicities. Clinical presentation may include manifestations of myopathy (muscle pain or tenderness). The most serious documented risks include the development of rhabdomyolysis, which can lead to secondary acute kidney injury, and rare reports of fatal or non-fatal hepatic failure.

Officially Documented Findings and Actions

Overdose Focus Regulatory Statement
Specific Antidote Not available; no specific treatment is known.
Treatment Mandate Symptomatic and supportive care is required.
Key Markers Markedly elevated Creatine Kinase (CK) and/or AST/ ALT levels are primary indicators of toxicity.

Immediate medical assistance is required if an overdose is suspected. Government health guidance specifies that emergency medical services must be contacted immediately if the affected individual collapses, has a seizure, or is unresponsive. The medication must be immediately discontinued if myopathy is diagnosed or CK levels are found to be markedly elevated. The official labeling confirms that hemodialysis is not expected to be of clinical benefit in accelerating drug elimination due to high plasma protein binding.

Advertisements

Therapeutic Uses of Stator (Rosuvastatin)

What Stator (Rosuvastatin) Treats: Main Uses and Benefits

Stator (Rosuvastatin) is commonly used as a component of therapy that addresses conditions related to systemic imbalance, primarily focusing on managing abnormally elevated blood lipid markers, including high low-density lipoprotein cholesterol (LDL-C) and triglycerides. This medication is considered relevant for key indications such as primary hyperlipidemia, mixed dyslipidemia, and inherited conditions like familial hypercholesterolemia. It provides support that helps bring these critical lipid markers into a more manageable range.

The primary role of Rosuvastatin is to support the management of long-term cardiovascular risk. It is commonly applied in high-risk scenarios, whether in primary prevention for adults with risk factors or in secondary prevention for patients who have already experienced a major vascular event. The use of this medication assists with maintaining functional stability and supports general well-being during symptomatic phases. It is commonly used in the management of the projected risk of major events like myocardial infarction and nonfatal stroke.

“This medication is applied in addressing the impact of lipid-driven vascular stress, providing support that helps bring critical lipid markers into a more manageable range.”


Quick Fact: Support for Lipid-Driven Risk

Context of Use Condition Category Primary Benefit
Chronic Management Dyslipidemia, Atherosclerosis Contributes to managing the long-term physiological impact related to chronic lipid conditions

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Stator (Rosuvastatin) is subject to specific population eligibility rules defined by government regulatory agencies.

Contraindications and Prohibited Groups

The medicine is contraindicated and mathbfmust not be used by patients with:

  • Active liver disease, including unexplained, persistent elevations of hepatic transaminase levels.
  • Pregnancy or lactation (breastfeeding).
  • Myopathy (muscle disease) or in patients receiving concomitant Cyclosporine.
  • Severe renal impairment (creatinine clearance <30 ml/min) [All doses, SmPC standard].
  • Known hypersensitivity to any component of the product.

Eligibility-Related Restrictions

Use is restricted or conditional for several groups:

  • Age: Approved for adults. Pediatric use is established for children mathbf7 to 17 years with specific types of familial hypercholesterolemia. Use in children under 6 years is not recommended. Patients over mathbf70 years require special caution and a lower starting dose.
  • Organ Function: The mathbf40 mg dose is contraindicated in patients with moderate renal impairment (CrCl <60 ml/min) and in those with predisposing factors for myopathy.
  • Ancestry: The mathbf40 mg dose is contraindicated for mathbfAsian patients due to documented increased systemic exposure.
  • Reproductive Status: Females of childbearing potential must use mathbfeffective contraception during treatment.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Stator (Rosuvastatin) governs interactions through mandates intended to manage systemic drug exposure and control additive pharmacodynamic risks.


Exposure Restrictions and Prohibitions

The most significant interactions are driven by the inhibition of specific transporter proteins (OATP1B1 and BCRP), which causes a documented increase in rosuvastatin plasma concentration. Consequently, co-administration with Ciclosporin is formally contraindicated by regulatory bodies. Other substances that increase exposure, such as certain Anti-viral agents (including Atazanavir/Ritonavir) and the kinase inhibitor Regorafenib, necessitate a mandated maximum daily dose restriction, often 10 mg or lower, to limit systemic levels. The combination with Gemfibrozil is an interaction that regulatory bodies state should be avoided.


Additive Risk and Timing Rules

A separate category covers pharmacodynamic interactions that increase the officially documented risk of adverse outcomes. Co-administration with Fibrates or Colchicine increases the risk of skeletal muscle effects. Stator is also documented to prolong the International Normalized Ratio (INR) when combined with Coumarin Anticoagulants (e.g., Warfarin). Furthermore, to prevent reduced absorption, Aluminum and Magnesium Hydroxide Combination Antacids must be administered at least 2 hours apart from Stator.


Population Considerations

The profile notes that Asian Patients exhibit an increased rosuvastatin systemic exposure. The risk of myopathy is also heightened in populations with advanced age or renal impairment when co-administered with interacting medicines.

Advertisements

Mechanism of Action

The mechanism of action for Rosuvastatin is based on a dual molecular strategy affecting hepatic cholesterol homeostasis: reducing internal production and enhancing external clearance.

Inhibition of Hepatic Cholesterol Synthesis

The drug acts as a competitive inhibitor of the enzyme HMG-CoA reductase (HMGCR), the rate-limiting step in the liver's Mevalonate pathway. By blocking this enzyme, the drug directly curtails the cell's ability to produce its own cholesterol. This action immediately leads to a state of intracellular cholesterol deficiency within the hepatocyte.

Upregulation and Enhanced Systemic Clearance

In response to the internal cholesterol deficit created by HMGCR inhibition, liver cells initiate a compensatory response: they rapidly increase the number and activity of Low-Density Lipoprotein (LDL) receptors on their surface. This upregulation significantly enhances the liver's capacity to bind and internalize LDL particles from the circulating blood. The resulting physiological effect is an increased catabolism (removal) of these lipoproteins from the systemic circulation, which works synergistically with the reduced production to reduce the concentration of circulating lipoproteins.

Modulation of Vascular Signaling (Pleiotropic Effect)

Inhibition of the Mevalonate pathway also depletes the supply of key isoprenoid intermediates. Since these intermediates are vital for regulating certain small cell signaling proteins, their reduction can modulate vascular function independent of the primary lipid-lowering effect, contributing to altering signaling within endothelial cells.

Advertisements

Dosage and Administration Information

The administration of Stator (Rosuvastatin) is defined by established guidelines, providing a standardized protocol for its long-term use.

Administration Scope

Instruction Guideline
Route of administration The medicine is taken via the oral route only.
Dosing schedule The overall approved dosage range is 5 mg to 40 mg once daily. Treatment typically initiates at 10 mg or 20 mg daily, with the 40 mg dose generally reserved for patients with severe hypercholesterolemia.
Timing in relation to meals (if applicable) Rosuvastatin may be administered with or without food, at any time of the day.
Preparation requirements (if applicable) The tablet must be swallowed whole.
Age-group administration rules A starting dose of 5 mg once daily is recommended for older adults (e.g., > 70 years) and specific populations, such as those of Asian descent, due to known pharmacokinetic differences.
Missed-dose rules If a scheduled daily dose is missed, instructions advise patients to not take an extra dose. Instead, the patient should continue the treatment schedule with the next regularly scheduled dose.
Special procedural conditions Dose adjustments are based on lipid level assessment and are typically conducted after intervals of 2 to 4 weeks or more. If certain antacids are used, they must be taken at least 2 hours after rosuvastatin administration.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Daily (once daily)
Use-context constraints Administration is dependent on lipid level response and is subject to population-specific and drug co-administration dosage limits.

Resulting Procedural Structure

Established step sequence:

  • Initiate therapy at the designated starting dose, taken once daily via the oral route.
  • The tablet must be swallowed whole without crushing or breaking.
  • Maintain the current daily dose for at least 2 to 4 weeks before any evaluation for dose adjustment is performed.

Connection to the overall use protocol (2–4 sentences): The established guidelines provide a controlled, long-term protocol, defining the fixed oral route and once-daily frequency. This structure indicates that dosage titration is a gradual, controlled process, permitting adjustment within the approved 5 mg to 40 mg range after sufficient time has passed for lipid level assessment, and adhering to explicit constraints for specific patient populations.

Advertisements

Recent Clinical Evidence

Stator (Rosuvastatin): Recent Clinical Evidence

Stator, containing the active substance Rosuvastatin, is a medication classified as an HMG-CoA reductase inhibitor, commonly referred to as a statin. Research on rosuvastatin primarily focuses on its role in managing dyslipidemia (abnormal cholesterol levels) and reducing the risk of cardiovascular events.


Core Efficacy: Lipid Management

Clinical trials have consistently shown that rosuvastatin is associated with significant reductions in low-density lipoprotein cholesterol (LDL-C) levels. These studies typically compare rosuvastatin to placebo or other statins, evaluating the percentage change in lipid profiles over periods ranging from 6 to 52 weeks. The efficacy appears to be dose-dependent, with higher doses generally yielding greater reductions in LDL-C.


Cardiovascular Risk Reduction

Major research trials have evaluated the long-term impact of rosuvastatin on preventing cardiovascular events. These large-scale studies assessed outcomes such as nonfatal myocardial infarction (heart attack), stroke, and the need for coronary revascularization procedures. Findings suggest that rosuvastatin use is associated with a reduced incidence of these major events in individuals with or at risk for cardiovascular disease. Evidence supports its use not only in secondary prevention (after an event) but also in primary prevention for certain high-risk patients.


Safety Profile Overview

The safety profile of rosuvastatin has been assessed across numerous trials. Common side effects reported are generally mild and may include headache, myalgia (muscle pain), and nausea. Rare but serious side effects, such as rhabdomyolysis or severe liver problems, are closely monitored in clinical settings. The overall benefits are generally considered to outweigh the risks in appropriate patient populations, according to major regulatory assessments.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Stator (Rosuvastatin) (FAQ)

Q: What is the main purpose of Stator (Rosuvastatin)?

Official documents describe the drug’s purpose as an addition to diet and exercise for managing cholesterol. It is used to reduce elevated levels of LDL-C (often called 'bad' cholesterol) and triglycerides, while also increasing HDL-C (often called 'good' cholesterol). This combined action is intended to reduce the risk of major cardiovascular events like heart attack and stroke.

Q: What are the key eligibility restrictions described in official documents for Stator?

Contraindications listed in the official prescribing information include having active liver disease or acute liver failure. Regulatory documents also advise caution for individuals who have predisposing factors that may increase the risk of muscle problems, such as inadequately treated hypothyroidism.

Q: Can Stator be taken by people with pre-existing kidney issues?

Official guidance addresses the use of the drug in people with kidney impairment. For individuals with severe kidney impairment not undergoing dialysis, the maximum dose listed in regulatory documents is reduced. It is noted that kidney issues may increase the overall risk of developing muscle-related side effects.

Q: Can Stator be taken at the same time as blood pressure medication?

The official label explicitly lists specific drug interactions, such as cyclosporine, certain antivirals, and aluminum/magnesium hydroxide antacids. Blood pressure medications are not named as a general class requiring a blanket restriction. However, a healthcare professional should review all co-administered medicines.

Q: Can older adults generally use Stator safely, based on official information?

Regulatory documents include special considerations for older adults. For individuals over 70 years, the official starting dose may be lower. It is also noted that advanced age (≥ 65 years) is listed as a potential factor that could predispose a person to developing muscle-related side effects.

Q: Why are regular blood tests sometimes required when using Stator?

Regulatory information indicates that blood tests are used for two main reasons. They help a healthcare professional check how well the liver is functioning, both before starting the drug and at certain intervals. Tests are also used to assess lipid levels to determine if a dosage adjustment is needed over time.

Q: Does Stator help with conditions other than high cholesterol?

Official regulatory documents indicate the drug is also indicated for use in reducing risk of cardiovascular events. Specifically, it is approved for reducing the risk of major heart events, such as heart attack and stroke, in certain patients who are determined to be at an increased risk, even if they do not yet show clinical signs of coronary heart disease.

Q: What are the most commonly reported side effects of Stator?

Based on clinical trial data summarized in official labels, common side effects reported by individuals taking the drug include headache, nausea, abdominal pain, weakness, and mild muscle pain.

Q: Are muscle aches and cramps a frequent concern when taking Stator?

Mild pain in the muscles is specifically reported as one of the common side effects listed in clinical trial data for the drug.

Q: Is it common to experience joint pain while on Rosuvastatin?

Joint pain is noted in official information as one of the mild side effects reported by individuals taking this medication.

Q: Does Stator interact with common over-the-counter pain relievers?

While no interaction was specifically found with acetaminophen (a common pain reliever), general official guidance recommends caution with all co-administered drugs. Patients are also advised not to exceed the maximum daily dosage of acetaminophen due to potential liver risks.

Q: Is Stator generally intended for lifelong use, based on condition?

The drug is often used as part of a long-term management plan for chronic conditions like high cholesterol. Official sources note that it is safe and works best when taken for an extended period, which is common practice for statin therapy.

Q: Can women who are pregnant or breastfeeding use Stator?

Official guidance is available regarding use during pregnancy and breastfeeding, as the drug is generally contraindicated for use during both periods.

Q: Is Stator suitable for use in children or adolescents, according to guidelines?

Official labeling includes use as an addition to diet to decrease cholesterol for certain young people. This use is specifically outlined for children and teenagers aged 8 to 17, or 7 to 17 for specific inherited cholesterol conditions.

Q: What do official sources say about the potential for memory issues with Stator?

Regulatory documents note that cognitive impairment, such as memory loss or confusion, has been observed in some patients receiving statins. These reports are generally not serious and are described as being reversible upon stopping the medicine.

Q: Why do people sometimes stop taking Stator?

Although the drug is often used long-term, official sources indicate that side effects may lead to a decision to discontinue the medication. Reported side effects that might prompt cessation include persistent headaches, muscle pain, or elevations in liver enzymes.

Q: Is the efficacy of Stator supported by large-scale research studies?

The official indications and approvals for Stator were granted based on results from large-scale, controlled clinical trials. These studies investigated its effectiveness in managing cholesterol and reducing the risk of major cardiovascular events.

Q: Where can I find official, non-commercial information about Stator?

Authoritative, non-commercial information can be found on government agency websites. Examples include the US Food and Drug Administration (FDA) label, the NIH’s DailyMed and MedlinePlus drug information pages, and the websites of other national drug regulatory bodies.

Q: Are there any restrictions on strenuous exercise while taking Stator?

The official label advises caution for patients with predisposing factors for myopathy, which is a condition involving muscle tissue damage. While not specifically restricting exercise, the risk of muscle-related side effects is a documented concern that is often discussed when engaging in strenuous physical activity.

Q: Is Stator primarily used for LDL cholesterol or triglyceride management?

Official documents indicate the drug is used to reduce elevated levels of Total Cholesterol, LDL-C, and triglycerides, and to increase HDL-C. However, its main mechanism is focused on reducing the production and increasing the clearance of LDL cholesterol.

Q: What are the general expectations for managing cholesterol levels with Stator?

Official guidance suggests that cholesterol levels may begin to drop within approximately four weeks. The overall therapeutic goal is to achieve cholesterol reduction and subsequently reduce the chance of heart events.

Q: Does Stator interact with common supplements like CoQ10?

Official sources note that there is currently no clear evidence to show that taking CoQ10 supplements provides a health benefit when taken with the drug. Separately, certain antacids containing aluminum or magnesium hydroxide have documented interaction rules requiring separation of doses by at least two hours.

Q: Are headaches a common initial side effect when starting Stator?

Headache is listed in clinical trial summaries as one of the most common side effects reported by people taking this medication.

Q: How is Stator described in official regulatory documents?

Official regulatory documents describe it as an HMG-CoA reductase inhibitor, which belongs to the class of drugs known as statins. It is used alongside diet and exercise to lower certain types of cholesterol and reduce the risk of cardiovascular events.

Q: What evidence exists regarding the use of Stator for prevention of events?

Regulatory approvals include the use of this drug for the primary prevention of major cardiovascular events (like heart attack and stroke) in certain patients determined to be at an increased risk. This indication is supported by established clinical trial data.

Q: What defines the safety classification of Stator?

The safety classification is defined by the official warnings, precautions, and contraindications listed in the regulatory prescribing information. This includes documented risks for muscle problems, potential liver effects, and interactions with other drugs.

Q: Are there any known interactions with herbal supplements?

The official label includes specific warnings regarding interactions with certain products, such as avoiding red yeast rice and being cautious with St. John's wort. Official documents advise that the use of any supplements should be reviewed by a healthcare professional.

Q: Does Stator have a known effect on blood sugar levels?

Regulatory documents note that increases in hemoglobin A1 c and fasting serum glucose levels have been reported with the use of certain statins. This indicates a potential effect on blood sugar monitoring.

Q: Is Stator classified as a high-intensity statin in official documents?

Based on expected LDL cholesterol reduction, the 20 mg and 40 mg dosage strengths are generally classified in treatment guidelines as high-intensity statin therapy. This classification indicates that these doses aim to achieve a significant reduction in LDL cholesterol.

Q: What are the reported signs of a serious, but rare, muscle-related side effect?

Regulatory documents describe potential signs of a serious side effect, such as unusual muscle pain, tenderness, or weakness, especially if accompanied by fatigue or fever. These are potential warning signs of a serious, rare muscle condition known as rhabdomyolysis.

Q: Is it true that Stator can cause changes in sleep patterns?

Reports compiled by regulatory bodies indicate that sleep disturbances, such as insomnia, have been noted as potential adverse events associated with the statin class of medications.

Q: How does Stator affect 'good' HDL cholesterol?

Official documents state that a therapeutic goal of the medication is to increase the amount of HDL cholesterol (often described as 'good' cholesterol) in the blood, in addition to lowering other lipid levels.

Q: Is there a link between Stator and new-onset diabetes risk?

Official information indicates that there is evidence suggesting this drug, like the statin class generally, may be associated with a small increase in blood sugar levels and the risk of new-onset diabetes in some individuals.

Q: Can Stator be taken by people with a history of thyroid issues?

Inadequately treated hypothyroidism is listed as a predisposing factor that may increase the risk of muscle-related side effects. Official guidance advises that thyroid levels should be managed before starting this medication.

Q: Is it necessary to avoid grapefruit or grapefruit juice while taking Stator?

Official guidance notes that, unlike some other statins, consuming grapefruit juice is generally considered safe when taking this particular medication.

Q: What official information is available about hair loss as a side effect?

Hair loss (alopecia) is reported in official adverse event monitoring systems as a rare side effect associated with the medication.

Q: Is Stator considered to be in the same class as Lipitor (atorvastatin)?

Both Stator (rosuvastatin) and Lipitor (atorvastatin) belong to the same pharmacological class. They are both classified as HMG-CoA reductase inhibitors, which is the definition of a statin drug.

Q: Does Stator thin the blood?

The mechanism of action is focused on cholesterol synthesis, not directly on blood thinning. However, the official label notes that the medication can affect the International Normalized Ratio (INR) in patients who are also taking blood-thinning medications.

Advertisements

How should Stator (Rosuvastatin) be stored and disposed of?

Storage and Disposal of Rosuvastatin Tablets

Official labeling requires rosuvastatin tablets to be stored at Controlled Room Temperature, which is specified as 68 F to 77 F (20 C to 25 C), and kept in a dry place. It must be stored in the container it came in, tightly closed, and kept away from excess heat and moisture (not in the bathroom). The medication must always be stored out of the reach of children and safety caps must be locked.

Expired or unused rosuvastatin should be safely discarded using a drug take-back program or by following specific federal guidelines for household disposal. These guidelines require mixing the medicine with an undesirable substance (such as coffee grounds) and sealing it before placing it in the trash. It is explicitly instructed not to flush this medicine down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Stator (Rosuvastatin) found in:

A-Z Index: